



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Review Article

Development and Clinical Application of Phosphorus-Containing Drugs

Hanxiao Yu ^a, He Yang ^{b,*}, Enxue Shi ^{c,*}, Wenjun Tang ^{a,d,*}^a State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, 345 Ling Ling Road, Shanghai 200032, China^b Shenzhen Grubbs Institute, Southern University of Science and Technology, Shenzhen, 518055, China^c State Key Laboratory of NBC Protection for Civilian, Beijing 102205, China^d School of Chemistry and Material Sciences, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Sub-lane Xiangshan, Hangzhou 310024, China

ARTICLE INFO

Article history:

Received 19 July 2020

Received in revised form 12 August 2020

Accepted 13 August 2020

Available online 25 August 2020

Keywords:

Phosphorus-containing drugs

Prodrugs

Drug modification

Phosphite, phosphate

ABSTRACT

Phosphorus-containing drugs belong to an important class of therapeutic agents and are widely applied in daily clinical practices. Structurally, the phosphorus-containing drugs can be classified into phosphotriesters, phosphonates, phosphinates, phosphine oxides, phosphoric amides, bisphosphonates, phosphoric anhydrides, and others; functionally, they are often designed as prodrugs with improved selectivity and bioavailability, reduced side effects and toxicity, or biomolecule analogues with endogenous materials and antagonistic endoenzyme supplements. This review summarized the phosphorus-containing drugs currently on the market as well as a few promising molecules at clinical studies, with particular emphasis on their structural features, biological mechanism, and indications.

Contents

1. Introduction	2
2. Nomenclature of P-Containing Molecules	3
2.1. P(III)-containing molecules	3
2.2. P(V)-Containing Molecules	3
3. Classification of P (V)-Containing Drugs	4
3.1. Phosphomonoester and Phosphodiester Drugs	4
3.1.1. Phosphomonoester Drugs	4
3.1.2. Phosphodiester Drugs	8
3.2. Phosphoric Amide Drugs	9
3.3. Phosphonate, Phosphinate, and Phosphine Oxide Drugs	11
3.4. Other Phosphate Drugs	13
3.5. Bisphosphonate and Phosphoric Anhydride Drugs	14
3.5.1. Bisphosphonate Drugs	14
3.5.2. Phosphoric Anhydrides Drugs	15
3.6. Miscellaneous	15
4. Conclusion and Outlook	16
CRedit author statement	16
Conflict of interest	16
References	16

* Corresponding authors.

** Correspondence to: W. Tang, State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, 345 Ling Ling Road, Shanghai 200032, China.

E-mail addresses: yanghe@sioc.ac.cn, (H. Yang), exshi@sina.com, (E. Shi), tangwenjun@sioc.ac.cn. (W. Tang).

Table 1
Nomenclature of P(III)-containing molecules

Phosphorus bound only to oxygen and/or carbon		Phosphorus bound directly to sulphur	Phosphorus bound directly to nitrogen	
Phosphite	Phosphonite	Phosphorothioite	Phosphoamidite	Phosphonamidite
Phosphinite	Phosphine	Phosphonothioite	Phosphorodiamidite	Phosphinamidite
		Phosphorodithioite	Phosphonodiamidite	Phosphotriamidite

1. Introduction

Phosphorus belongs to one of the most essential elements of life and is extensively distributed in nature. For example, phosphate-containing units are important building-blocks for nucleotides, which are the basic structures of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Phosphorus-containing compounds are involved in vital processes or

functions ranging from biochemistry, biogeochemistry, ecology, agriculture, to industry. For example, one of the most famous agricultural and industrial application was dichlorvos (DDVP), which used to be a broad spectrum insecticide and acaricide but was banned since 1998 due to its high toxicity in inhibiting acetyl cholinesterase [1]. Phosphorus-containing drugs constitute to be an important class of therapeutic agents targeting a wide range of diseases. Their development has long attracted significant

Table 2
Nomenclature of P (V)-containing molecules

Phosphorus bound only to oxygen and/or carbon		Phosphorus bound directly to nitrogen		P=S bonds & Phosphorus bound directly to sulphur or fluorine			Bisphosphonate/ Phosphoric anhydrides	
Phosphate	Phosphonate	Phosphoroamidate	Phosphonamidate	Phosphorothioate	Phosphonothioate	Phosphorodithioate	Bisphosphonate	Pyrophosphate
Phosphinite	Phosphine oxide	Phosphorodiamidate	Phosphinamidate	Dithiophosphinate	Thiophosphate	Thiophosphonate	Triphosphate	Tetraphosphate
		Phosphonodiamidate	Phosphotriamidate	Phosphorodithioate	Thiophosphinate	Phosphorofluoridate		




Fig. 3. Structures of secondary and tertiary alcohol-derived phosphomonoester drugs 2-4.

groups, which are typically bound directly to oxygen (phosphate), nitrogen (phosphoramidate), carbon (phosphonate, phosphinate, and phosphine oxide), sulphur (phosphorothionate), and fluorine (phosphorofluoridate) [18]. Other major types of P(V)-containing drugs include thiophosphate containing P=S bonds, phosphoric anhydrides with one or multiple P-O-P units, and bisphosphonate bearing P-C-P units, as shown in Table 2.

3. Classification of P (V)-Containing Drugs

(Mark* means the drug is not on the market)

3.1. Phosphomonoester and Phosphodiester Drugs

The development of phosphoester and phosphodiester drugs have attracted significant attention ever since menadiol sodium diphosphate (Synkayvite®) was first developed and approved by FDA in 1941

(Figure 1) [19]. Today more than 37 phosphoesters and phosphodiester are in the market and their combinational drugs are not even included.

Most phosphoester drugs are developed based on the modification of currently existing drugs to improve efficacy, by tethering a phosphoric monoester to the drug molecule through a hydroxyl functionality, while most phosphodiester drugs were derived from essential biomolecules or bio-markers, such as glycerol, nucleotides, and enzymes.

3.1.1. Phosphomonoester Drugs

Phosphomonoester features the direct connection of the phosphate group to the hydroxyl group of an existing drug molecule, which is designed to circumvent the insufficient solubility issue of the parent drug. The presence of phosphomonoester moiety improves the efficacy and the aqueous solubility of the corresponding drug molecule during the absorption and distribution process (Figure 2) [5]. The phosphate prodrug undergoes conversion to its parent drug *in vivo* and inorganic phosphate through the interaction with alkaline phosphatase, an abundant enzyme in human body [20].




Fig. 4. Structures of primary alcohol-derived phosphomonoester drugs 5-13.




Fig. 5. Structures of phenol-derived phosphomonoester drugs 15-17.

Clindamycin (**1**) is a 50S ribosomal subunit inhibitor for treating gram-positive bacterial infections (Figure 3). However, irritation at the injection site was observed with this parent drug. The topical application of clindamycin phosphate (Cleocin/Dalacin-S/Evoclin®, **2**) can replace the parent drug clindamycin (**1**) due to its higher aqueous solubility and efficient release of drugs *in vivo* [7]. Clindamycin is also in combination with benzoyl peroxide (Benzaclin®2000), tretinoin (Ziana/Veltin®2006), adapalene and benzoyl peroxide* (phase III) in treating acne [6,21]. Fosfluconazole (Prodif®2003, **3**) has been considered as a triazole antifungal and lanosterol 14 α -demethylase (CYP51A1) inhibitors. It is prescribed for the treatment of fungal infections caused by *Cryptococcus neoformans* and *Candida* [22]. The application of fosfluconazole increases the efficacy of the parent drug fluconazole *in vivo* due to the rapid transport of phosphate derivative across cell membranes [23]. Polyestradiol phosphate (PEP) (Estradurin/Estradurine®1957, **4**) is a polymeric synthetic estrane steroid for the treatment of metastatic prostate cancer [24]. As slow hydrolysis rate is presented for phosphoesters of secondary and tertiary alcohols

due to decreased catalytic efficiency of the enzyme by steric hindrance at the cleavage site, polyestradiol phosphate (**4**) represents a long-lasting prodrug with slow release of estradiol in the body [25].

Effective clinical applications are also achieved by phosphatization of related biomolecules, such as endogenous structures. This is exemplified by vidarabine monophosphate (**5**), a phosphorylated vidarabine, actively treating the systematic herpes virus infection (Figure 4) [26]. Its fluorine derivative, fludarabine phosphate (Beneflur/Fludara/Oforta®1991, **6**), is a DNA synthesis inhibitor and applied in therapy of chronic lymphocytic leukemia (CLL) [27–28]. Many molecules of this type are still in clinical trials. For instance, triciribine phosphate* (TCN-P, **7**) is currently at phase II clinical studies and is designed for the treatment of breast cancer, acute myeloid leukemia and ovarian cancer by inhibiting protein kinase B (PKB) at the target AKT1 [29–30]. Pyridoxal phosphate* (PLP, **8**) as a purinergic P2 receptor antagonist, is currently tested in tardive dyskinesia (phrase II) [31]. Fostemsavir* (**9**) is under phase III stage as envelope glycoprotein inhibitors, gp120 attachment inhibitors, and HIV gp120 protein inhibitors [32].





Fig. 6. Structures of steroid hormone-derived sodium phosphate drugs 18–22.

Tedizolid phosphate (Sivextro®2014, **10**) is one of the most important protein synthesis inhibitors, 50S ribosomal subunit inhibitors, and oxazolidinone antibiotics. This pharmaceutical product is used for the treatment of methicillin resistant to *staphylococcus aureus* and bacterial skin infections [33]. Other phosphomonoester drugs derived from primary alcohols include benfotiamine (Milgamma/Neurostop®) (**11**) for vitamin B1 deficiency, chlorinated drugs dichlorvos (DDVP)* (**12**) and triclofos* (**13**) [34–35].


Besides parent drugs containing aliphatic alcohols, those with phenolic moieties are also applicable to design as phosphomonoester prodrugs (Figure 5) [36]. For example, fosfestrol sodium* (**15**) is an estrogen receptor (ER) agonist in prostatic cancer therapy and this drug is derived from the phosphorylation of hormone drug fosdestrol* (Distilbene/Stilbestrol/Stilbetin®) (**14**). Fosfosal (Aydolid/Disdolen®) (**16**) is a salicylic acid

phosphate serving as a nonsteroidal anti-inflammatory and analgesic drug (NSAID) [37]. As a topoisomerase (DNA) II alpha (TOP2A) inhibitor, etoposide phosphate (Etopophos®1996, **17**) exhibits sufficient aqueous solubility to minimize the probability of drug precipitation by injection, which is widely used for treating testicular cancer, small cell lung cancer, multiple myeloma, acute lymphoblastic leukemia, and non-Hodgkin's lymphoma [5,38–40].


The modification by forming sodium and calcium phosphates also shows a tremendous improvement in aqueous affinity of the parent drugs, facilitating drug absorption and distribution, as well as relieving skin irritation. One of the most classical examples is betamethasone, a steroid medication which acts as a glucocorticoid receptor (GR) agonist for various infections, allergic diseases, and immune inflammations (Figure 6) [41–42]. Betamethasone sodium phosphate (**18**) is involved in intramuscular use when the oral therapy




23: Fosphenytoin Disodium
(Cerebyx/ Fostoin/ Pro-Epanutin/
Cereneu/ Prophenytoin/ Prodilantin®1996)




24: Fospropofol Disodium
(Lusedra/Aquavan®2008)




25: Riboflavin Sodium Phosphate
(Hyryl/ Ribo®)




26: Menadiol Sodium Diphosphate
(Synkayvite®1941)




27: (S)-Ornidazole Disodium Phosphate*
(NDA apply 2019)



29: Calcium Glycerophosphate
(NDA apply 2019)



28: Gadofosveset trisodium*
(Ablavar/ AngioMARK/ Vasovist®2015)



30: Fosamprenavir Calcium (Lexiva/ Telzir®2003)

Fig. 7. Structures of sodium and calcium phosphate drugs 23-30.




Fig. 8. Structures of phosphodiester drugs 31-34 and cyclic phosphodiester drugs 35-37.

is not feasible. This prodrug is also used in clinical application to interact with drugs such as betamethasone acetate (Celestone Soluspan®1965) and fradiomycin sulfate (Rinderon-A®), to stimulate additional inhibitory activity against cell wall biosynthesis [43–44].

The anabolic steroids analogues, dexamethasone sodium phosphate (Acidexam/Alba-Dex/Decadrol/Dexacort/Hexadrol/Oradexon®) (19) is

developed to replace its parent drug testosterone in clinical application. For example, aciont (Visulex®) is currently in phase II clinical trial for treating uveitis [8,45–46]. Other synthetic glucocorticoid corticosteroid analogues include hydrocortisone sodium phosphate (Hydrocortone®1960, 21) and prednisolone sodium phosphate (Prednesol/Predsol/Predsolan/ Solu-Predalone/Solucort®) (20), which are also used in combination




Fig. 9. Time line of main phosphoric amide drugs.




Fig. 10. Structures of phosphoromonoamidate drugs 38–43.

with sulfacetamide sodium (Vasocidin®1988) and phenoxazoline* [9,47–48]. In addition, estramustine phosphate sodium (Emcyt/Estracyt®) (22) has been approved as an alkylating agent to treat prostatic cancer [10].

Most phosphomonoester drugs are pharmacologically designed from either existing clinical drugs or naturally occurring compounds by esterification to form sodium and calcium phosphate (Figure 7). Fosphenytoin disodium (Cerebyx/Fostoin/Pro-Epanutin/Cereneu/Prophenytoin/Prodilantin®1996, 23) is applied to deliver phenytoin more efficiently due to its excellent water-solubility [13,49–50]. Fospropofol disodium (Lusedra/Aquavan®2008, 24) is also a water-soluble form of fospropofol which is a hypnotic alkyphenol derivative to be related to the effects on GABA-mediated chloride channels in the central nervous system (CNS) [51–53]. This drug molecule can be hydrolyzed by alkaline phosphatase *in vivo* to propofol, possessing greater potential than propofol for hyperlipidemia at long-time administration. It is noted that riboflavin sodium phosphate (Hyryl/Ribo®) (25) is developed from natural riboflavin (vitamin B2) and menadiol sodium diphosphate (Synkayvite®1941, 26) is modified from Vitamin K4 [19]. Other promising and important phosphomonoester drugs currently under clinical studies include gadofosveset trisodium*

(Ablavar/AngioMARK/Vasovist®2015, 28), (S)-ornidazole disodium phosphate* (NDA apply) (27), and mifamurtide sodium* [54–56]. There are only a few calcium phosphate drugs on the market. Calcium glycerylphosphate (or calcium glycerophosphate, 29) is a mineral supplement and fosamprenavir calcium (Lexiva/Telzir®2003, 30) is a derivative of HIV-1 protease inhibitor and antiretroviral drug amprenavir [57–58].

3.1.2. Phosphodiester Drugs

Besides phosphomonoester drugs designed from direct connection between the phosphate group and a hydroxyl group of the parent drug, phosphodiester drugs derived from natural and biologically active chemicals constitute another important class of phosphate drugs (Figure 8). For example, (S)-ethylisothiuronium diethylphosphate (Difetur/Ravimig/Raviclust/Raviten®1997, 31) is a specific inhibitor of inducible nitric oxide (NO) synthase on hepatic NO production level [59–60]. Other distinct phosphodiester structures are cyclic esters such as bucladesine, cifostodine (neurodrug) (37), and adenosine cyclophosphate (36) [17,61]. Bucladesine sodium (Actosin®) (35) is modified from bucladesine, which is a nucleotide derivative of phosphodiesterase (PDE)




Fig. 11. Structures of phosphorodiamidate 44–47.




Fig. 12. Structures of phosphorotriamidate 48–55.

inhibitor to mimic the action of endogenous cAMP [62–63]. Derived from a natural choline compound in brain, choline alfoscerate (α -GPC) (Brezal/Delectit/Gliatilin®) (33) was designed as a parasympathomimetic acetylcholine precursor to deliver choline across the blood-brain barrier (BBB) for treating Alzheimer's disease and other dementias [64–65]. BBB is a highly selective semipermeable border of endothelial cells. Solutes are not permitted to cross into extracellular fluid of neurons reside-containing CNS from the circulating blood, such as pathogens. As a result, one major challenge in drug discovery of the CNS therapy is to allow the therapeutics to pass through BBB [66–68]. It is believed that the high polarity of choline alfoscerate makes it readily pass through BBB to provide good therapeutic effect [69]. Other renowned phosphodiester drugs are exemplified by

colfosceril palmitate (Surfexo®/Neonatal™) (34) applied as a pulmonary surfactant, and vitamin B12-derived methylcobalamine* (MeCbl/MeB12) (32) as a cardiovascular drug [70–72].

3.2. Phosphoric Amide Drugs

Phosphoric amide drugs, such as phosphoromonoamidates, phosphorodiamidates and phosphorotriamidates, are designed as prodrugs from the corresponding active parent drugs by direct connection between nitrogen and phosphorus atom. Figure 9 delineated the time line for the development of main phosphoric amide drugs. Among them, fosaprepitant dimeglumine (EMEND/Ivemend/Proemend®2007, 38) is a prodrug of aprepitant, which is used to prevent chemotherapy-induced nausea and vomiting (CINV), and postoperative nausea and vomiting (PONV) [73]. Creatine and phosphocreatine are naturally occurring chemicals within the body primarily stored in skeletal muscle. Because phosphocreatine is capable of anaerobically donating a phosphate group to ADP to regenerate ATP, and excess ATP can be dephosphorylated during periods of low muscle activity to convert creatine to phosphocreatine, phosphocreatine is a crucial energy buffer in body muscle cells. The pharmacological role of creatine phosphate sodium (39) is to facilitate recycling of ATP for reducing the risk of muscular and cardiovascular disease [74–75]. (See Fig. 10.)

Sofosbuvir (Sovaldi/Elbanovir/Resof®2013, 40) is developed as a prodrug in antihepatitis C treatment. This phosphoric amide compound is metabolized *in vivo* to triphosphate form as the active antiviral agent,




Fig. 13. Structures of tenofovir slafenamide fumarate 56.




Fig. 14. Time line of main phosphonate, phosphinate, phosphine oxide and other drugs.

COVID-19. Remdesivir is reported to inhibit murine hepatitis virus (MHV) replication, potently inhibit SARS-CoV, and MERS-CoV in primary human airway epithelial cells. By comparing with its parent adenosine nucleoside without possessing the phosphoramidate moiety, 1'-cyano 4-aza 7,9-dideazaadenosine C-nucleoside (GS-441524, **42**), remdesivir has provided markedly enhanced antiviral activities. It is more potent ($EC_{50} = 0.03 \mu\text{mol/L}$) in inhibition of MHV than GS-441524 ($EC_{50} = 1.1 \mu\text{mol/L}$). In addition, remdesivir has shown 3 to 30 times more active than GS-441524 in all tested coronaviruses (CoVs) due to its more efficient metabolism of remdesivir [14–16].

Cyclophosphamide is a vital structure of phosphorodiamidate drugs and is commonly featured by the presence of two P-N bonds. Drugs of this type have been used as nitrogen mustard alkylating agents for cancer treatment (Figure 11). It has been reported that the phosphoryl group is involved as the carrier structure of alkylation reaction at β -chloroethylamino functionality, which can be selectively activated by phosphoramidate in tumor cells for alkylation of DNA through a cationic aziridinium intermediate [3,82]. Cyclophosphamide (Cytosan/Endoxan/Endoxana/Neosar/Revimmune/Sendoxan®1959, **44**) is a chemotherapy medicine suppressing the immune system [83–84]. Normally, it is in drug interactions with cimetidine, diclofenac and salazosulfapyridine (SASP)* (phase II) for clinical treatment of solid tumor, metastatic pancreatic cancer, as a Histamine H2 receptor antagonist, alkylating agent, COX inhibitor, PGSI and LT synthesis inhibitor [85–87]. In addition, the combination of cyclophosphamide and capecitabine* (phase II) is applicable for treatment of mammary cancer by further inhibiting nucleoside metabolism and thymidylate synthase (TYMS) [88–89]. As the alkylating agents, ifosfamide (Holoxan/Ifex/Mitoxana®1987, **45**) is used for treating testicular cancer, breast cancer, solid tumor, lung cancer, sarcoma, lymphoma, and ovarian cancer, while trofosfamide (Ixoten®) (**46**) is used for targeting malignant tumor [90]. Several phosphorodiamidate drugs are currently under investigation as alkylating agents and DNA synthesis inhibitors such as glufosfamide* (**47**) currently in phase III clinical trial for treating advanced breast cancer and pancreatic cancer [91–92].

Phosphorotriamidate alkylating agents bearing aziridine rings are also important nitrogen mustards as antineoplastic agents such as azetepa* (**48**), uredepa* (**49**), dipin* (**50**), fopurine* (**51**), and meturedepa* (**52**)

(Figure 12) [17]. Glyciphosphoramidate* (**53**) bearing β -chloroethylamino moieties is an effective DNA crosslinking agent with antitumor activities [93–94]. However, some phosphorotriamidate are enzyme inhibitors such as urease inhibitors tolfamide* (**54**) and flurofamide* (**55**) [95–97].

Tenofovir alafenamide fumarate (Vemlidy®2016, **56**) is a phosphate-containing drug having distinct chemical structures with respect to the phosphoric amides moieties [98]. It possesses a phosphorus center connecting directly with one P-C, P-N, and P-N bond (Figure 13). As a HBV nucleotide reverse transcriptase inhibitor (NRTI), this drug is approved for treatment of hepatitis B. It is also involved in a series of cooperative drugs for treatment of AIDS. For example, it is used in combination with emtricitabine (Descovy®2016), rilpivirine hydrochloride, and emtricitabine (Odefsey®2016) to inhibit additional nucleoside analog and non-nucleoside, HIV nucleoside analog reverse transcriptase [99–100]. Alternatively, it is combined with darunavir ethanolate, cobicistat and emtricitabine (Symtuza®2017) to inhibit additional HIV-1 protease and cytochrome P450 3A (CYP3A) enzyme [101].

3.3. Phosphonate, Phosphinate, and Phosphine Oxide Drugs

Compounds containing a phosphorus atom binding directly to one or more carbon atoms feature different structure characters from phosphates, usually rendering a more hydrophilic surface and having better chemical stability. In a wide range of technologically important applications in chemical synthesis, a good catalytic activity is achieved by using phosphonate, phosphinate, and phosphine oxide as the catalyst due to the stronger adsorption capacity of the P-C bond for metal ions and organic molecules [102]. Fig. 14 delineates the progress in the development of phosphonate, phosphinate, phosphine oxide, and related drugs.

The synthetic phosphonate analogues are mainly used as acyclic enzyme inhibitors, normally as phosphonate analogue prodrugs in clinical application (Figure 15). For example, the phosphonic acid derivative, foscarnet sodium (Foscavir/Triapten/Virudin®1991, **57**) was developed from foscarnet (phosphonomethanoic acid) in treatment of herpes viruses, including drug-resistant cytomegalovirus (CMV) and herpes simplex viruses (HSV-1 and HSV-2) [103–104]. It selectively acts against the pyrophosphate binding site due to the structural mimic of anion pyrophosphate




Fig. 18. Structures of phosphinate and phosphine oxide drugs 69–73.




Fig. 19. Structures of phosphorofluoridate drug 74 and phosphorothiate drugs 75–76.

[105–106]. Antiparasitic drug metrifonate (Bilarcil/Memobay/ProMem®) (58) is an acetylcholinesterase inhibitor [107]. However, this drug was banned due to its high toxicity of metabolism dichlorvos in plants [108]. The phosphonodipeptides are also developed possessing antibacterial and antifungal properties, such as alafosfalin* (59) and LeuAlaP* (60) which are used as antibacterial drugs [109–110].

Phosphonate derivatives of heterocyclic bases have shown to inhibit nucleoside phosphorylase (Figure 16) [17]. Adefovir dipivoxil (ADV) (Preceon/Hepsera®, 62), a prodrug of pivoxil, is formulated to improve the fat solubility *in vivo* from adefovir, which is more polar and has a low oral bioavailability because of its free phosphonic acid functionality [3,111]; Tenofovir disoproxil phosphate (Tefovir®2017) (63) also inhibits nucleotide analogues reverse-transcriptase (NtRTI) for hepatitis B therapy. The interaction of tenofovir disoproxil phosphate with emtricitabine and efavirenz (2017) has been applied for AIDS treatment [112–113]. In addition, (S)-HPMPA (61) possess potent and selective inhibitory activities against a broad spectrum of DNA viruses [114].

The high value of biological compounds with structures containing C-P bonds was gradually recognized with the identification of more and more naturally produced phosphonates. Their unique structural features and chemical biosyntheses are widely exploited in drug discovery and agricultural application (Figure 17) [115]. For example, fosfomycin is a

phosphoenolpyruvate (PEP) analogue that inhibits the enzyme UDP-N-acetylglucosamine-3-enolpyruvyltransferase (MurA). It has been reported that this drug inhibits the biosynthesis of bacterial cell wall by alkylating an active site cysteine residue [116–118]. Fosfomycin sodium (CONTEPO/Fosfocine/Fosmicin-S/ZOLYD®1996, 64), as an antibiotic, was primarily used to treat bladder infections [119]. This drug is also involved in drug combination with amikacin sulfate* (phase II) for further inhibiting protein 30S ribosomal subunit [120–121]. Another clinical application of aliphatic phosphate is fosfomycin trometamolium (Monuril/Monuroil®1996, 65), which is mainly used for lowering urinary tract infection caused by sensitive bacteria [3,121–122]. Drugs in this category remain in clinical trials including antiviral drugs fosarilate* (68), cardiovascular drugs fostedil* (66) and mifobate* (67) [17,123].

The replacement of the P-O bonds of phosphates with two or three P-C bonds has been applied in phosphorus-containing drug design (Figure 18). Unlike most angiotensin converting enzyme (ACE) inhibitors of cardiovascular drugs, fosinopril (Monopril®1991, 69) with a phosphinate structure is a more positive choice for treating hypertension and chronic heart failure through the body elimination by both renal and hepatic pathways [124–125]; fosinoprilat is developed from the de-esterification of fosinopril, which competitively binds to ACE *in vivo* [126]. Ridaforolimus* (Taltorvic®phase III, 70) is a small-molecule inhibitor of rapamycin




Fig. 20. Time line of bisphosphonate and phosphonic anhydrides drugs




Fig. 21. Structures of non-nitrogenous bisphosphonate drugs 77–80.




Fig. 22. Structures of nitrogenous bisphosphonate drugs 81–87.




Fig. 23. Structures of nitrogenous bisphosphonate drugs 88–90.

(mTOR), interfering growth, division, metabolism, and angiogenesis of tumor cells [127]. As for phosphine oxide drugs containing three P-C bonds, fosazepam (71) is a water soluble derivative of diazepam (Valium1963), which is substituted with a dimethylphosphoryl group to improve its solubility in water [128]. This drug is a benzodiazepine derivative and acts as a positive allosteric modulator of the GABA type A receptors (GABA_A) [129]. Small-molecule drug brigatinib (Alunbrig®2016, 72) acts as both an anaplastic lymphoma kinase (ALK) and a epidermal growth factor receptor (EGFR) inhibitor. It is also used in targeted cancer therapy [130–131]. Fosenazide (73) is a neurodrug with strong inhibiting activities of adrenaline and 5-hydroxytryptamine (serotonin) [17].

3.4. Other Phosphate Drugs

Besides the above introduced drugs, there are a series of phosphate drugs with close biological similarities, such as irreversible acetylcholinesterase inhibitors, dyflos and ecothiopate iodide (Figure 19) [132]. Dyflos (Flopropryl®) (74) is a parasymphatomimetic drug acting as irreversible anticholinesterase and being able to induce delayed peripheral neuropathy. This drug is used in ophthalmology as a miotic agent in veterinary medicine and treatment of chronic glaucoma [133]. Both dyflos and ecothiopate iodide (Ecothiopate Iodide®) (75) are used as ocular antihypertensives for chronic glaucoma therapy by covalently binding to serine group at the




Fig. 24. Structures of pyrophosphate drugs 91–93.

active site of the cholinesterase [134]. Amifostine (Ethyol®1995, 76) is a cytoprotective adjuvant and is used as an organic phosphorothiate prodrug for cancer chemotherapy and radiotherapy. After administration, it is hydrolyzed *in vivo* by alkaline phosphatase to the active cytoprotective thiol metabolite as a DNA-binding chemotherapeutic agent [135].

3.5. Bisphosphonate and Phosphoric Anhydride Drugs

Main bisphosphonate and phosphoric anhydride drugs have been developed since 1970s (Figure 20), and more than 14 medical molecules of bisphosphonates and 8 phosphoric anhydrides are developed (both not include drug combination). Both of them constituted with at least two phosphorus functionalities, whose definition was based on P-containing linkages of 'P-C-P' or 'P-O-P'.

3.5.1. Bisphosphonate Drugs

Bisphosphonate drugs are characterized by the presence of two phosphonate moieties connected with a substituted carbon atom. Substitution with a hydroxyl group on the carbon atom has been shown to reduce

osteoclastic activity and inhibit bone resorption, construction, and reconstruction. Drugs of this type are used for the treatment of hypercalcemia caused by osteoporosis, deformable osteoarthritis, and bone tumor [136–137].

As bone resorption inhibitors, non-nitrogenous bisphosphonate drugs belong to the first generation of anti-osteoporotic drug (Figure 21). They are absorbed and metabolized by osteoclasts into ATP analogues and have been approved for preventing and treating osteoporosis in postmenopause [138–139]. For example, etidronate disodium and clodronate disodium contain both hydroxyl and chlorine substitutions on the carbon atom connecting the two phosphate groups, respectively [3–4]. Etidronate disodium (Calcimux/Didronel/Etidron®1977, 77) has been approved for the treatment of osteoporosis and Paget's disease of bone, while chlorophosphonic acid clodronate disodium (Bonafos/Abioklad/Clasteon/Clastoban/Loron/Lytos/Ostac®1986, 78) is used for reducing vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma, and pain related in fracture (reduction in inflammatory markers like IL-1 β , IL-6, and TNF- α) [140–142]. Chlorophosphonic acid clodronate disodium is also involved in drug interaction with clodronic




Fig. 25. Structures of nucleoside pyrophosphate drugs 94-98.

acid and hyaluronic acid* (phase I) in osteoarthritis therapy due to its potent anti-inflammatory and analgesic effects [143].

Tiludronate disodium hydrate (Skelid®2014, **79**) is a bisphosphonate derivative with a *p*-thiochlorobenzene ring-containing side chain for treatment of navicular disease. This drug is metabolized by osteoclasts to inhibit ATP in the cell competitively [144]. Another non-nitrogenous bisphosphonate drug is ¹⁸⁸Re-HEDP* (phase II) (**80**) which contains rare metal rhenium [145].

Unlike the above-introduced first generation of bisphosphonates, the second and third generation of bisphosphonate drugs have been developed with nitrogen-containing substitution or nitrogen-containing heterocycles in side chains, respectively. This specific design allow these drugs to interfere farnesylation and protein geranylation of ATP by combining with farnesyl pyrophosphate (FPP) synthetase and isopentene pyrophosphate (IPP) of mevalonate channel to form a stable ternary complex [3,146–147].

Drugs belong to the second generation of bisphosphonate derivatives include pamidronate disodium (Aminomux/Aredia®1991, **81**) for preventing bone loss and strengthening bone, ibandronate sodium hydrate (Boniva/Bondronat/Bonviva/Bondenza/Iasibon®1996, **82**) for use in drugs interactions with colecalciferol (Bonviva Plus®2013) to treat osteoporosis and osteoporosis in post-menopausal women (phase III), alendronate sodium (Alendros/Almerol/Avalent/Binosto/Bonalon/Fosamax/Fosamc/Onclast/Steovess/Teiroc®1995, **83**) which has been approved in drug combination with colecalciferol (Adrovanse/Fosamance®2005), and alendronate, in combination with calcitriol (Maxmarvil®) (Figure 22) [3–4]. In addition, LLP2A alendronate* (phase I) (**84**), neridronic acid (Attila/Nerixia®) (**85**), and neridronate sodium (2002) (**86**) are used for treating osteoporosis and Paget's disease [148–150]. It should be indicated that incadronate disodium (Bisphonal®1997, **87**) is a nitrogen-containing bisphosphonate drug that contributes a cycloheptyl substituted amino group [151].

The third generation of bisphosphonate derivatives have been reported to possess more effective activity than drugs from the first two generations (Figure 23). For example, risedronate sodium hydrate (Actonel/Benet/Acrel®1998, **88**) is involved in the interaction between risedronate sodium with colecalciferol (Risenex plus/Risenex M®2010) [152–153]. Zoledronic acid hydrate (Aclasta/Orazol/Reclast®2000, **89**) has been shown to interact with prednisolone* (phase III) and minodronic acid hydrate (Bonoteo/Recalbon®2009, **90**) [154–155].

3.5.2. Phosphoric Anhydrides Drugs

Phosphoric anhydrides drugs are another major class of phosphates derivatives, including pyrophosphates, nucleoside diphosphates, nucleoside triphosphates, and tetraphosphates.

Pyrophosphates are phosphorus oxyanions containing two phosphorus atoms in a P-O-P linkage. Drugs of this type normally exist as pyrophosphate salt. The pyrophosphates drugs are developed from mimicking biochemical molecules with respect to the phosphate-phosphate bonds which are related to some endogenous important compounds, such as adenosine diphosphate (ADP) and adenosine triphosphate (ATP). For example, ferric pyrophosphate citrate (Triferic®2011, **91**) is an iron(III)

pyrophosphate for iron supplementation (Figure 24). It is used as a key element in the formation of new red blood cells for anemic dialysis patients [156–157]. Cocarboxylase (TPP/ThPP/ThDP) (**92**) is a hiamine (vitamin B1) derivative for VB1 supplementation which is produced by the enzyme thiamine diphosphokinase [158]. As apoptosis stimulant and platinum-pyrophosphate agent, PT-112 (phase II) (**93**) is a platinum complex for treatment of solid tumor, multiple myeloma, and hepatoma [159].

Other nucleoside derivatives are developed from the endogenous compounds with high-energy phosphate, such as adenosine diphosphate (ADP) and adenosine triphosphate (ATP) (Figure 25). As the nucleoside diphosphates analogues, citicoline sodium (CerAxon/Nicholin/Somazina®) (**94**) can improve cardiovascular and cerebrovascular circulation, and is used in treatment of brain damage, apoplexy, cerebrovascular, and Parkinson's disease. This drug is hydrolyzed to choline and cytosine nucleosides in circulatory system and after crossing the blood-brain barrier, it is recombined again in the brain tissue to promote the biosynthesis of phospholipids in the cell membrane in brain tissue [160–161]. Flavin adenine dinucleotide sodium (FAD) (Adeflavin/Flavitan/Flaziren/Wakadenin®) (**95**) is approved for treating acne, keratitis, vitamin B2 deficiency, conjunctivitis, acne rosacea, eczema, seborrheic dermatitis, and stomatitis. It is a redox-active coenzyme derivative with flavin mononucleotide, which is involved with several important enzymatic reactions of riboflavin in metabolism [162].

It is widely known that adenosine triphosphate (ATP) is the most direct energy source involved in metabolism of organism. As its nucleoside analogues, adenosine triphosphate disodium hydrate (Adesinon®, **96**) is approved for treating supraventricular arrhythmia and peripheral vascular disease in clinical practice. It is anticipated that a special antiplatelet drug, cangrelor (Kengreal/Kengrexal®2015, **97**) has phosphorus oxyanions containing two phosphorus atoms in a P-O-P linkage [163]; one carbon atom and one phosphorus atom in P-C-P linkage, it is used to interfere P2Y12 receptors reversibly, which involves in ADP-induced platelet aggregate [164].

As a P2Y2 purinoceptor receptor (P2Y2) agonist, diquafosol tetrasodium (Diquas/Prolacria®2010, **98**) is a tetraphosphate and has been approved for treating xerophthalmia [165].

3.6. Miscellaneous

Phosphorus-containing pharmaceutical molecules also include phosphorodithioate drugs and more (Figure 26). Thiotepea (Tepadina/Thioplex®1959, **99**) is an alkylating agent and has been approved in treatment of gastrointestinal tumor, mammary, bladder, and ovarian cancer [166–167]. Malathion (Ovide®1982, **100**) has been reported to inhibit acetylcholinesterase (AChE) and is used for treating head louse [168]. As an anti-rheumatic agent and phosphorus triethyl-phosphine coordinated gold salt, auranofin (Ridaura®) (**101**) is a nonsteroidal anti-inflammatory and analgesic drug. Besides treating rheumatoid arthritis, it also shows moderate effects in clinical treatments of HIV infection, amebiasis,




Fig. 26. Structures of other phosphate drugs 99–101.

tuberculosis and ovarian cancer, which may be against on coronavirus (COVID-19) [169–170].

4. Conclusion and Outlook

This review summarizes the phosphorus-containing drugs on the market and related promising agents that are currently under clinical studies. Most P-containing drugs are designed as prodrugs for reducing side effects and toxicity, increasing the selectivity and bioavailability. Drugs of this type are characterized by either direct connection between phosphate group and the hydroxyl group of the parent drugs or possessing an indirect linker bearing function groups such as amino and halogens. The solubility and aqueous affinity of parent drugs are improved significantly. While slow conversion rate is confronted for prodrugs derived from the phosphomonoester of secondary and tertiary alcohols in some cases, such as sodium phosphates and calcium phosphates, they are all developed by simple substitutions from chemical synthesis.

In a wide range of important clinical applications, phosphoric anhydrides and polyphosphates derivatives of P-containing drugs are developed by mimicking biochemical molecules *in vivo*, including some endogenous structures (ATP and ADP) and enzymes. For example, bisphosphonates with hydroxyl substitution on the carbon atom are active for bone resorption, construction, and reconstruction by reducing osteoclastic activities. Future generations of phosphorus-containing osteoporosis drugs and others with more complicated chemical structures share the same advantage.

It has been showcased that various forms of P-containing drug molecules have been developed from a rapidly progressing clinical research with various biological activities including anticancer, antibacterial, anti-inflammatory, anti-osteoporosis, and cerebrovascular circulation. Most common applications are consistently developed due to their potential advantages, including prodrugs modifying and resemblance to biochemical entities. It is certain that phosphorus-containing drugs will continue to be an important class of valuable therapeutic agents in clinical applications.

CRedit author statement

Hanxiao Yu: Information collecting, original draft writing.

He Yang: Writing-draft, review, editing.

Enxue Shi: Conceptualization.

Wenjun Tang: Conceptualization, writing-draft, review, editing, Supervision.

Conflict of interest

The authors declare that they do not have any conflicts of interest.

Acknowledgments

We are grateful to the Strategic Priority Research Program of the Chinese Academy of Sciences XDB20000000, CAS (QYZDY-SSW-SLH029), NSFC (21725205, 21432007, 21572246), STCSM-18520712200, and K. C. Wong Education Foundation.

References

- Okoroiewu HU, Iwara IA. Dichlorvos toxicity: a public health perspective. *Interdiscip Toxicol.* 2018;11:129–37. <https://doi.org/10.2478/intox-2018-0009>.
- Andrew W. *Pharmaceutical Manufacturing Encyclopedia*. 3rd ed.. William Andrew Publishing, Norwich NY: Elsevier; 2007; p. 56m-57m. ISBN-13: 9870815515265.
- Yao Q, Reng L, Ran M, He J, Xiang D. Review on the structures of phosphorus-containing drugs used in clinical practice. *Hua xue Shi ji.* 2019;41:139–46. <https://doi.org/10.13822/j.cnki.hxsj.2019006737>.
- Rodriguez JB, Gallo-Rodriguez C. The role of the phosphorus atom in drug design. *Chem Med Chem Rev.* 2019;14:1–28. <https://doi.org/10.1002/cmdc.201800693>.
- Karaman R. *Prodrugs Design: A New Era (Pharmacology- Research, Safety Testing and Reaction)*. 1th ed.. Nova Biomedical, New York: Nova Science Publisher, Inc; 2014; 112–5 ISBN: 9781631177019.
- Thielitz A, Gollnick H. Recent therapeutic developments for acne. *Expert Rev Dermatol.* 2013;8:37–50. <https://doi.org/10.1586/edm.12.70>.
- Cambazard F. Clinical efficacy of Velac®, a new tretinoin and clindamycin phosphate gel in acne vulgaris. *J Eur Acad Dermatol Venerol.* 1998;11:20–7. <https://doi.org/10.1111/j.1468-3083.1998.tb00903.x>.
- Kulkarni PS, Bhattacharjee KE, Srinivasan BD. Anti-inflammatory effects of betamethasone phosphate, dexamethasone phosphate and indomethacin on rabbit ocular inflammation induced by bovine serum albumin. *Curr Eye Res.* 2010;35:43–7. <https://doi.org/10.3109/02713688109019971>.
- Esselinckx W, Bacon PA, Ring EFJ, Crooke D, Collins AJ, Demottaz D. A Thermographic assessment of three intra-articular prednisolone analogues given in rheumatoid synovitis. *Br J Clin Pharmacol.* 1978;5:447–51. <https://doi.org/10.1111/j.1365-2125.1978.tb01653.x>.
- Benson R, Hartley-Asp. Mechanisms of action and clinical uses of estramustine. *Cancer Invest.* 2009;8:375–80. <https://doi.org/10.3109/07357909009012056>.
- Pol S, Corouge M, Vallet-Pichard A. Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. *Hepa Med Evid Res.* 2016;8:21–6. <https://doi.org/10.2147/HMER.S62014>.
- Fung A, Jin Z, Dyatkina N, Wang G, Beigelman L, Deval J. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis c virus polymerase. *Antimicrob Agents Chemther.* 2014;58:3636–45. <https://doi.org/10.1128/AAC.02666-14>.
- Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Addition of epigallocatechin gallate 400mg to sofosbuvir 400mg + daclatasvir 60mg with or without ribavirin in treatment of patients with chronic hepatitis c improves the safety profile: a pilot study. *Sci Rep.* 2019;9:13593. <https://doi.org/10.1038/s41598-019-49973-6>.
- Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature.* 2016;531:381–5. <https://doi.org/10.1038/nature17180>.
- Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *Mbio Asm Org.* 2018;9:e00221-18. <https://doi.org/10.1128/mBio.00221-18>.
- Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734™). Gilead Sciences, Inc. <https://www.fda.gov/media/137566/download>; Jun, 2020.
- Yu X. Development of Phosphorus-containing Drugs. , 19Pharma Industry; 1988; 513–20. <https://doi.org/10.16522/j.cnki.cjph.1988.11.017>.
- Quin LDA. *Guide to Organophosphorus Chemistry*. 1st ed.. Wiley Interscience. Hoboken: A John Wiley & Sons. Inc; 2000 ISBN: 0471318248.
- Song PS, Moore TA. Mechanism of the photodephosphorylation of menadiol diphosphate. a model for bioquantum conversion. *J Am Chem Soc.* 1968;90:6507–14. <https://doi.org/10.1021/ja01025a049>.
- Gani D, Wilkie J. Stereochemical, mechanistic, and structural features of enzyme-catalysed phosphate monoester hydrolyses. *Chem Soc Rev.* 1995;55–63. <https://doi.org/10.1039/CS9952400055>.
- Kawashima M, Hashimoto H, Sáenz A, Ono M, Yamada M. Clindamycin phosphate 1.2%-benzoyl peroxide 3.0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase iii, multicentre, randomised, single-blinded, active-controlled, parallel-group study. *Br J Dermatol.* 2015;172:494–503. <https://doi.org/10.1111/bjd.13265>.
- Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ. Discovery of fluconazole, a novel antifungal agent. *Rew Infect Dis.* 1990;12:S267–71. https://doi.org/10.1093/clinids/12.supplement_3.s267.
- Johnson DS, Li JJ. *The Art of Drug Synthesis*. Wiley Interscience, Hoboken: A John Wiley & Sons. Inc; 2007; 80–1 9780471752158.
- Jönsson G, Diczfalusy E, Plantin LO, Röhl L, Birke G. Estradurin® (Polyestradiol Phosphate) in the treatment of prostatic carcinoma. A clinical and Steroid Metabolic Study. *Eur J Endocrinol.* 1963;44:S3–S41. <https://doi.org/10.1530/acta.0.044S003>.
- Safadi M, Oliyai R, Stella VJ. Phosphoryloxymethyl carbamates and carbonates—novel water-soluble prodrugs for amines and hindered alcohols. *Pharma Res.* 1993;10:1350–5. <https://doi.org/10.1023/a:1018934200343>.
- Whitley RJ, Tucker BC, Kinkel AW, Barton NH, Pass RF, Whelchel JD, et al. Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans. *Antimicrob Agent Chemother.* 1980;18:709–15. <https://doi.org/10.1128/AAC.18.5.709>.
- Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. *Semin Oncol.* 1990;17:49–62.
- Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. *J Clin Oncol.* 1991;9:175–88. <https://doi.org/10.1200/JCO.1991.9.1.175>.
- Hoffman K, Holmes FA, Fraschini G, Esparza L, Frye D, Raber MN, et al. Phase I-II study: tricitabine (tricyclic nucleoside phosphate) for metastatic breast cancer. *Cancer Chemother Pharmacol.* 1996;37:254–8. <https://doi.org/10.1007/BF00688325>.
- Phase I. Pharmacokinetic and pharmacodynamic study of tricitabine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. *Invest New Drugs.* 2011;29:1381–9. <https://doi.org/10.1007/s10637-010-9479-2>.
- Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gemington G, Addington D, et al. Treatment recommendations for tardive dyskinesia. *Canada J Psychia.* 2019;64:388–99. <https://doi.org/10.1177/0706743719828968>.
- Lataillade M, Zhou N, Joshi SR, Lee S, Stock DA, Hanna GJ, et al. Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir. *J Acquir Immune Defic Syndr.* 2018;77:299–307. <https://doi.org/10.1097/QAI.0000000000001602>.
- Rybak JM, Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. *Infect Dis Ther.* 2015;4:1–14. <https://doi.org/10.1007/s40121-015-0060-3>.

- [34] Stracke H, Lindemann A, Federlin KA. Benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. *Exp Clin Endocrinol Diabetes*. 1996;104:311–6. <https://doi.org/10.1055/s-0029-121146>.
- [35] Murakami T, Iwamuro Y, Chinaka S, Takayama N, Komatsu T. Highly sensitive detection of organophosphorus pesticides using 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin. *Anal Sci*. 2015;31:1325–8. <https://doi.org/10.2116/analsci.31.1325>.
- [36] Odlo K, Klaceness J, Rongved P, Hansen TV. Synthesis of combretastatins A-1 and B-1. *Tetra Lett*. 2006;47:1101–3. <https://doi.org/10.1016/j.tetlet.2005.12.037>.
- [37] Jeromin L. Clinical follow-up of prostatic cancer patients under intermittent treatment with fosfestrol and bromocriptine. *Urol Int*. 1988;43:41–3. <https://doi.org/10.1159/000281431>.
- [38] Shah JC, Chen JR, Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. *Pharma Res*. 1989;6:408–12. <https://doi.org/10.1023/a:1015935532725>.
- [39] Budman DR, Lgwemezie LN, Kaul S, Behr J, Lichtman S, Schulman P, et al. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. *J Clin Oncol*. 1994;12:1902–9. <https://doi.org/10.1200/JCO.1994.12.9.1902>.
- [40] Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. *Eur J Cancer*. 1998;34:1514–21. [https://doi.org/10.1016/S0959-8049\(98\)00228-7](https://doi.org/10.1016/S0959-8049(98)00228-7).
- [41] Papangkorn K, Prendergast E, Higuchi JW, Brar B, Higuchi WI. Noninvasive ocular drug delivery system of dexamethasone sodium phosphate in the treatment of experimental Uveitis rabbit. *J Ocular Phar Therapeu*. 2017;33:1–10. <https://doi.org/10.1089/jop.2017.0053>.
- [42] Golladay ES. Treatment of keloids by single intraoperative perilesional injection of repository steroid. *Sou Med J*. 1988;81:736–8. <https://doi.org/10.1097/00007611-1988060000013>.
- [43] Roberts HJ. Local injection of a preparation containing two betamethasone esters in the treatment of noninfectious musculoskeletal disorders. *J Am Geria Soc*. 1965;13:275–91. <https://doi.org/10.1111/j.1532-5415.1965.tb02677.x>.
- [44] Okada N, Hashimoto K, Sato K, Yamamura T, Yoshikawa K. Clinical Evaluation of Betamethasone 17,21-Dipropionate (Rinderson DP® Ointment and Cream) for Eczematous Dermatitis. *Skin Res*. 1992;34:402–8. doi:10.11340/skinresearch1959.34.402.
- [45] Jungsuwadee P, Dekan G, Stingl G, Epstein MM. Inhaled dexamethasone differentially attenuates disease relapse and established allergic asthma in mice. *Clin Immunol*. 2004;110:13–21. <https://doi.org/10.1016/j.clim.2003.09.003>.
- [46] Papangkorn K, Truett KR, Vitale AT, Jhaveri C, Scales DK, Foster CS, et al. Novel dexamethasone sodium phosphate treatment (DSP-Visulex) for noninfectious anterior Uveitis: a randomized phase I/II clinical trial. *Curr Eye Res*. 2018;44:185–93. <https://doi.org/10.1080/02713683.2018.1540707>.
- [47] Sunaga Y, Kurosawa M, Nemoto T, Fueki R, Kobayashi S. A case of hydrocortisone sodium succinate-induced asthma. *KITAKANTO Med J*. 1985;35:565–70. <https://doi.org/10.2974/kmj1951.35.565>.
- [48] Searles GE, DesGroselliers JP. Excipients in topical corticosteroid preparations in Canada. *Can Med Assoc J*. 1989;141:399–405.
- [49] Ramsay RE, Wilder BJ, Uthman BM, Garnett WR, Pellock JM, Barkley GL, et al. Intramuscular fosphenytoin (Cerebyx®) in patients requiring a loading dose of phenytoin. *Epilepsy Res*. 1997;28:181–7. [https://doi.org/10.1016/S0920-1211\(97\)00054-5](https://doi.org/10.1016/S0920-1211(97)00054-5).
- [50] Johnson J, Wrenn K. Inappropriate fosphenytoin use in the ED. *Am J Emer Med*. 2001;19:293–4. <https://doi.org/10.1053/ajem.2001.24471>.
- [51] Cooke A, Anderson A, Buchanan K, Byford A, Gemmill D, Hamilton N, et al. Water-soluble propofol analogues with intravenous anaesthetic activity. *Bioorg Med Chem Lett*. 2001;11:927–30. [https://doi.org/10.1016/S0960-894x\(01\)00088-9](https://doi.org/10.1016/S0960-894x(01)00088-9).
- [52] Bennett DJ, Anderson A, Buchanan K, Byford A, Cooke A, Gemmill DK, et al. Novel water soluble 2,6-dimethoxyphenyl ester derivatives with intravenous anaesthetic activity. *Bioorg Med Chem Lett*. 2003;13:1971–5. [https://doi.org/10.1016/S0960-894x\(03\)00346-9](https://doi.org/10.1016/S0960-894x(03)00346-9).
- [53] Chidambaran V, Costandi A, D'Mello A. Propofol: a review of its role in pediatric anesthesia and sedation. *CNS Drugs*. 2015;29:543–63. <https://doi.org/10.1007/s40263-015-0259-6>.
- [54] Turkbey B, Hoyt RF, Agarwal HK, Bernardo M, Sankineni S, Johnson L, et al. Magnetic resonance sentinel lymph node imaging of the prostate with gadofosveset trisodium-albumin: Preliminary Results in a Canine Model. *Acad Radiol*. 2015;22:646–52. <https://doi.org/10.1016/j.acra.2014.12.021>.
- [55] Duan Y, Zhang S, Liu X. Study on pharmacokinetics methodology of S(-)-ormidazol disodium phosphate. *J Sou Uni (Med Sci Ed)*. 2011;02.
- [56] Brosa M, García DMX, Mora J, Villacampa A, Pozo T, Adán C, et al. Economic considerations on the use of mifamurtide in the treatment of osteosarcoma in Spain. *Val Health*. 2014;17:A526–7. <https://doi.org/10.1016/j.jval.2014.08.1662>.
- [57] Lynch RJM. Calcium glycerophosphate and caries: a review of the literature. *Intern Dent J*. 2010;54:310–4. <https://doi.org/10.1111/j.1875-595X.2004.tb00004.x>.
- [58] Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naïve patients with HIV infection. *Drugs*. 2004;64:2101–24. <https://doi.org/10.2165/00003495-200464180-00014>.
- [59] Garvey EP, Oplinger JA, Tanourey GJ, Sherman PA, Fowler M, Marshall S, et al. Potent and selective inhibition of human nitric oxide Synthases. Inhibition by non-amino acid isothioureas. *J Bio Chem*. 1994;269:26669–76.
- [60] Vromen A, Southan SGJ, Salzman AL. Effects of S-isopropyl isothioureia, a potent inhibitor of nitric oxide synthase, in severe hemorrhagic shock. *Am Physiol Soc*. 1996;81:707–15. <https://doi.org/10.1152/jappl.1996.81.2.707>.
- [61] Petersen TS, Kristensen SG, Jeppesen JV, Grøndahl ML, Wissing ML, Macklon KT, et al. Distribution and function of 3',5'-Cyclic-AMP phosphodiesterases in the human ovary. *Mol Cell Endocrinol*. 2015;403:10–20. <https://doi.org/10.1016/j.mce.2015.01.004>.
- [62] Bucladesine Sodium Ye H. *World Clin. Drugs*. 1986;5.
- [63] Hosseini-Zare MS, Salehi F, Seyedi SY, Azami K, Ghadiri T, Mobasseri M, et al. Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylene-tetrazol-treated mice. *Eur J Pharm*. 2011;670:464–70. <https://doi.org/10.1016/j.ejphar.2011.09.026>.
- [64] Moreno MDJ. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. *Excerpta Medica*. 2002:178–93. [https://doi.org/10.1016/s0149-2918\(03\)90023-3](https://doi.org/10.1016/s0149-2918(03)90023-3).
- [65] Nikonov VV, Savitskaya IB, Beletsky AV. Choline alfoscerate in the treatment of acute ischemic stroke. *Emerg Med*. 2013;48:68–71. <https://doi.org/10.22141/2224-0586.1.48.2013.90391>.
- [66] Partridge WM. Blood-brain barrier drug targeting: the future of brain drug development. *Molec Inter*. 2003;3:90–105.
- [67] Partridge WM. Blood-brain barrier delivery. *Drug Discov Today*. 2007;12:54–61. <https://doi.org/10.1016/j.drudis.2006.10.013>.
- [68] Di L, Kerns EH, Carter GT. Strategies to assess blood-brain barrier penetration. *Expert Opin Drug Discov*. 2008;3:677–87. <https://doi.org/10.1517/17460441.3.6.677>.
- [69] Anfuso CD, Sipione S, Lupo G, Ragusa N, Alberghina M. Characterization of glycerophosphocholine phosphodiesterase activity and phosphatidylcholine biosynthesis in cultured retinal microcapillary pericytes. Effect of adenosine and endothelin-1. *Lipids*. 2003;38:45–52. <https://doi.org/10.1007/s11745-003-1030-z>.
- [70] Dechant KL, Faulds D. Colfosceril palmitate—a review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf® Neonatal™) in neonatal respiratory distress syndrome. *Drugs*. 1991;42:877–94. <https://doi.org/10.2165/00003495-199142050-00009>.
- [71] Kuwabara S, Nakazawa R, Azuma N, Suzuki M, Miyajima K, Fukutake T, et al. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. *Intern Med*. 1999;38:472–5. <https://doi.org/10.2169/internalmedicine.38.472>.
- [72] James SJ, Melynck S, Fuchs G, Reid T, Jernigan S, Pavliv O, et al. Efficacy of methylcobalamin and folic acid treatment on glutathione redox status in children with autism. *Am J Clin Nutr*. 2009;89:425–30. <https://doi.org/10.3945/ajcn.2008.26615>.
- [73] Garnock-Jones KP. Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy. *Drugs*. 2016;76:1365–72. <https://doi.org/10.1007/s40265-016-0627-7>.
- [74] Barcelos RP, Stefanello ST, Mauriz JL, González-Gallego J, Soares FAA. Creatine and the liver-metabolism and possible interactions. *Mini-Rev Med Chem*. 2016;16:12–8. <https://doi.org/10.2174/1389557515666150722102613>.
- [75] Green AL, Hultman E, Macdonald IA, Sewell DA, Greenhaff PL. Carbohydrate ingestion augments skeletal muscle creatine accumulation During creatine supplementation in humans. *J Physiol*. 1996;821–6. <https://doi.org/10.1152/ajpendo.1996.271.5.E821>.
- [76] Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. *J Bio Chem*. 2007; 282: 29812-29820. doi:<https://doi.org/10.1074/jbc.M705274200>.
- [77] Murakami E, Tolstykh T, Bao H, Niu C, Steuer HMM, Bao D, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. *J Bio Chem*. 2010;285:34337–47. <https://doi.org/10.1074/jbc.M110.161802>.
- [78] Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, et al. Drug authorization for sofosbuvir/ledipasvir (Harvoni) for chronic HCV infection in a real world cohort: a new barrier in the HCV care cascade. *PLoS One*. 2015;10:e0135645. <https://doi.org/10.1371/journal.pone.0135645>.
- [79] Greig SL. Sofosbuvir/velpatasvir: a review in chronic hepatitis C. *Drugs*. 2016;76:1567–78.
- [80] Heo YA, Deeks ED. Sofosbuvir/velpatasvir/voxilaprevir: a review in chronic hepatitis C. *Drugs*. 2018;78:577–87.
- [81] Ikeda Y, Ban J, Ishikawa T, Hashiguchi S, Urayama S, Horibe H. Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant *Staphylococcus aureus* cephalosporin T-91825. *Chem Pharm Bull*. 2008;56:1406–11. <https://doi.org/10.1248/cpb.56.1406>.
- [82] Griskevicius L, Yasar Ü, Sandberg M, Hiderstrand M, Eliasson E, Tybring G, et al. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. *Eur J Clin Pharmacol*. 2003;59:103–9. <https://doi.org/10.1007/s00228-003-0590-6>.
- [83] Foye LV, Chapman CG, Willitt FM, Adams WS. Cyclophosphamide: A preliminary study of a new alkylating agent. *Arch Intern Med*. 1960;106:365–7. <https://doi.org/10.1001/archinte.1960.03820030053009>.
- [84] Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. *Blood Rev*. 1992;6:163–73. [https://doi.org/10.1016/0268-960x\(92\)90028-o](https://doi.org/10.1016/0268-960x(92)90028-o).
- [85] Kohn FR, Sladek NE. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. *Biochem Pharm*. 1985;34:3465–71. [https://doi.org/10.1016/0006-2952\(85\)90719-1](https://doi.org/10.1016/0006-2952(85)90719-1).
- [86] Immonen K, Finne P, Grönhagen-riska C, Pettersson T, Klaukka T, Kautiainen H, et al. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. *Amyloid*. 2011;18:25–8. <https://doi.org/10.3109/13506129.2010.549252>.
- [87] Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. *Semin Immunopathol*. 2011;33:369–83. <https://doi.org/10.1007/s00281-011-0245-0>.
- [88] Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. *J Clin Oncol*. 2008;26:4899–905. <https://doi.org/10.1200/JCO.2008.17.4789>.
- [89] Pagnoux C. Updates in ANCA-associated vasculitis. *Eur J Rheumatol*. 2016;3:122–33. <https://doi.org/10.5152/eurjrheum.2015.0043>.

- [90] Jahnke K, Thiel E, Bechrakis NE, Willerdig G, Kraemer DF, Fischer L, et al. Ifosfamide or trofosfamide in patients with intraocular lymphoma. *J Neurooncol.* 2009;93:213–7. <https://doi.org/10.1007/s11060-008-9761-8>.
- [91] Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. *Eur J Cancer.* 2009;45:1589–96. <https://doi.org/10.1016/j.ejca.2008.12.022>.
- [92] Lacombe D. Glufosfamide: can we improve the process of anticancer agent development. *Exp Op Invest Drugs.* 2012;21:749–54. <https://doi.org/10.1517/13543784.2012.670218>.
- [93] Sun Y. Clinical phase II trial of a new antineoplastic drug - glyciophosphoramidate. *Clinical Trial.* 1984;6:273–26.
- [94] Juan L, Hong Z, Xun Z, Chen L, Qiang Y, Shu L, et al. Influence of zhuqin formula extract on the cellular and humoral immune response in cyclophosphamide-immunocompromised mice. *J Anim Plant Sci.* 2015;25:1335–43.
- [95] McCarty GW, Bremner JM, Lee JS. Inhibition of plant and microbial ureases by phosphoroamides. *Plant and Soil.* 1990;127:269–83. <https://doi.org/10.1007/BF00014435>.
- [96] Martens DA, Bremner JM. Effectiveness of phosphoroamides for retardation of urea hydrolysis in soils. *Soil Sci Soc Am J.* 1984;48:302–5. <https://doi.org/10.2136/sssaj1984.0361599500480002001>.
- [97] Ohta T, Shibata H, Kawamori T, Iimuro M, Sugimura T, Wakabayashi K. Marked reduction of helicobacter pylori-induced gastritis by urease inhibitors, acetohydroxamic acid and flurofamide, in mongolian gerbils. *Biochem Biophys Res Commun.* 2001;285:728–33. <https://doi.org/10.1006/bbrc.2001.5229>.
- [98] William E, James C. Tenofovir alafenamide tablets (Vemlidy). *Intern Med Alert.* 2017;39:3.
- [99] Clercq ED. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). *Biochem Pharma.* 2016;119:1–7. <https://doi.org/10.1016/j.bcp.2016.04.015>.
- [100] Clercq ED. Tenofovir at the crossroad of the therapy and prophylaxis of HIV and HBV infections. *J Cell Immunol.* 2020;2:23–30 <https://doi.org/>.
- [101] Deeks ED. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. *Drugs.* 2018;78:1013–24. <https://doi.org/10.1007/s40265-018-0934-2>.
- [102] Puziy AM, Poddubnaya OI, Gawdzik B, Tascón JMD. Phosphorus-containing carbons: preparation, properties and utilization. *Carbon.* 2020;157:796–846. <https://doi.org/10.1016/j.carbon.2019.10.018>.
- [103] Minor JR, Baltz JK. Foscamet sodium. *DICP.* 1991;25:41–7. <https://doi.org/10.1177/106002809102500109>.
- [104] Clercq ED. Antiviral drugs: current state of the art. *J Clin Virol.* 2001;22:73–89. [https://doi.org/10.1016/S1386-6532\(01\)00167-6](https://doi.org/10.1016/S1386-6532(01)00167-6).
- [105] Canestri A, Ghosn J, Wiriden M, Marguet F, Ktorza N, Boubezari I, et al. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. *Antivir Ther.* 2006;11:561–6.
- [106] Meyer PR, Rutvisuttinunt W, Matsuura SE, So AG, Scott WA. Stable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnet. *J Mol Biol.* 2007;369:41–54. <https://doi.org/10.1016/j.jmb.2007.03.006>.
- [107] Nordgren I, Bengtsson E, Holmstedt B, Petterson BM. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil®. *Acta Pharmacol Toxicol.* 2009;49:79–86. <https://doi.org/10.1111/j.1600-0773.1981.tb03256.x>.
- [108] Bakes D, Karalliedde L, Murray V, Maynard RL, Parkinson NHT. *Essentials of Toxicology of Health Protection: A Handbook for Field Professionals.* 2nd ed. Health Protection Agency, Oxford: Oxford University Press; 2012; 192–4 9780199652549.
- [109] Khomutov RM, Osipova TI, Khurs EN, Dzhavakhiya VG. Synthesis of alafosfalin and its phosphinic analogue and their fungicidal activity. *Mendeleev Commun.* 2008;18:295–6. <https://doi.org/10.1016/j.mcom.2008.11.001>.
- [110] Atherton FR, Hassall CH, Lambert RW. Synthesis and Structure-activity relationships of antibacterial phosphonopeptides incorporating (1-aminoethyl) phosphonic acid and (aminomethyl) phosphonic acid. *J Med Chem.* 1986;29:29–40. <https://doi.org/10.1021/jm00151a005>.
- [111] Reddy KR, Matelich MC, Ugarkar BG, Gómez-Galeno JE, DaRe J, Ollis K, et al. Pradefovir: a prodrug that targets adenovirus to the liver for the treatment of hepatitis B. *J Med Chem.* 2008;51:666–76. <https://doi.org/10.1021/jm7012216>.
- [112] Lu L, Yip B, Trinh H, Pan CQ, Han SHB, Wong CC, et al. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. *J Viral Hepat.* 2015;22:675–81. <https://doi.org/10.1111/jvh.12368>.
- [113] Martin P, Lau DT, Nguyen MH, Janssen HLA, Dieterich DT, Peters MG, et al. A treatment algorithm for the management of chronic Hepatitis B virus infection in the United States: 2015 update. *Clin Gastroenterol Hepatol.* 2015;13:2071–87. <https://doi.org/10.1016/j.cgh.2015.07.007>.
- [114] Clercq ED, Holý A, Rosenberg I, Sakuma T, Balzarni J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. *Nature.* 1986;323:464–7. <https://doi.org/10.1038/323464a0>.
- [115] Metcalf WW, Donk WA. Biosynthesis of phosphonic and phosphinic acid natural products. *Annu Rev Biochem.* 2009;78:65–94. <https://doi.org/10.1146/annurev.biochem.78.091707.100215>.
- [116] Brown ED, Vivas EI, Wslsh CT, Kolter R. MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in *Escherichia coli*. *J Bacteriol.* 1995;177:4194–7. <https://doi.org/10.1128/jb.177.14.4194-4197.1995>.
- [117] Zhu JY, Yang Y, Han H, Betzi S, Olesen SH, Marsilio F, et al. Enzymology: functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA). *J Bio Chem.* 2012; 287: 12657–12667. doi:10.1074/jbc.M112.342725.
- [118] Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. *Clin Microbiol Rev.* 2016;29:321–47. <https://doi.org/10.1128/CMR.00068-15>.
- [119] Tsuruoka T. Clinical pharmacology of fosfomycin sodium. *Antibiot Chemother.* 1996; 12:85–93.
- [120] Santoro A, Cappello AR, Madeo M, Martello E, Iacopetta D, Dolce V. Interaction of fosfomycin with the glycerol 3-phosphate transporter of *Escherichia coli*. *Biochimica et Biophysica Acta (BBA).* 2011;1810:1323–9. <https://doi.org/10.1016/j.bbagen.2011.07.006>.
- [121] Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. *Drugs.* 1997;53:637–56. <https://doi.org/10.2165/00003495-199753040-00007>.
- [122] García-Rodríguez JA, Martín IT, Baquero F, Cisterna R, Gobernado M, Linares F, et al. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study. *J Chemother.* 1997;9:394–402. <https://doi.org/10.1179/joc.1997.9.6.394>.
- [123] Yoshino K, Kohno T, Uno T, Morita T, Tsukamoto G. Organic phosphorus compounds 1.4-(Benzothiazol-2-yl) benzylphosphonate as potent calcium antagonistic vasodilator. *J Med Chem.* 1986;29:820–5. <https://doi.org/10.1021/jm00155a037>.
- [124] Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behloui H, Tu JV. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. *Can Med Assoc J.* 2008;178:1303–11. <https://doi.org/10.1503/cmaj.060068>.
- [125] Greenbaum R, Zucchelli P, Caspi A, Nouriel H, Paz R, Sclarovsky S, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. *Br J Clin Pharmacol.* 2000;49:23–31. <https://doi.org/10.1046/j.1365-2125.2000.01013.x>.
- [126] Duchin KL, Wacławski AP, Tu JI, Manning J, Frantz M, Willard DA. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. *J Clin Pharmacol.* 1991;31:58–64. <https://doi.org/10.1002/j.1552-4604.1991.tb01887.x>.
- [127] Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. *Future Oncol.* 2013;9:1883–92. <https://doi.org/10.2217/fon.13.141>.
- [128] Saintonge DMC, Vere DW, Sharman VL. Activity of fosazepam, a soluble analogue of diazepam. *Br J Clin Pharmacol.* 1976:494–6. <https://doi.org/10.1111/j.1365-2125.1977.tb00773.x>.
- [129] Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABA_A receptor subtypes and addiction. *Trends Neurosci.* 2011;34:188–97. <https://doi.org/10.1016/j.tins.2011.01.004>.
- [130] Huang W, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. *J Med Chem.* 2016;59:4948–64. <https://doi.org/10.1021/acs.jmedchem.6b00306>.
- [131] Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers Acquiring resistance to EGFR inhibitors. *Sci Transl Med.* 2013;5:199ra26. <https://doi.org/10.1126/scitranslmed.3002003>.
- [132] Lembeck F, Sewing K. *Pharmacological Facts and Figures.* 1st ed. Springer-Verlag Berlin Heidelberg. 1969; ISBN-13: 9780387900100. doi:10.1007/978-1-4684-6243-2.
- [133] Kanski JJ. Miotics. *Br J Ophthalmol.* 1968;52:936–7. <https://doi.org/10.1136/bjo.52.12.936>.
- [134] Gabelt B'AT, Hennes EA, Seeman JL, Tian B, Kaufman PL. H-7 Effect on outflow facility after trabecular obstruction following long-term echothiophate treatment in monkeys. *Invest Ophthalmol Vis Sci.* 2004;45:2732–6. <https://doi.org/10.1167/iovs.04-0083>.
- [135] Kouvaris JR, Kouloulas VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. *Oncologist.* 2007;12:738–47. <https://doi.org/10.1634/theoncologist.12-6-738>.
- [136] Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. *Mayo Clin Proc.* 2008;83:1032–45. <https://doi.org/10.4065/83.9.1032>.
- [137] Chhipa NMR, Sen DJ. Aminobiphosphonates in osteoporosis: a review. *Int J Drug Dev & Res.* 2013;5:120–32.
- [138] Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'- (β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. *J Bone Miner Res.* 1997;12:1358–67. <https://doi.org/10.1359/jbmr.1997.12.9.1358>.
- [139] Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and Drug Holidays. *Can Fam Physician.* 2014;60:324–33.
- [140] Kanis JA, Evanson JM, Russell RGG. Paget's bloom of bone : diagnosis and management. *Metab Bone Dis & Rel Res.* 1981;3:219–30. [https://doi.org/10.1016/0221-8747\(81\)90036-9](https://doi.org/10.1016/0221-8747(81)90036-9).
- [141] Ala-Houhala I, Saha H, Liukko-Sipi S, Ylitalo P, Pasternack A. Pharmacokinetics of clodronate in haemodialysis patients. *Nephrol Dial Transplant.* 1999;14:699–705. <https://doi.org/10.1093/ndt/14.3.699>.
- [142] Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J. MonEffect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. *Pharm Res.* 1995;12:916–22. <https://doi.org/10.1023/a:1016281608773>.
- [143] Arlov Ø, Öztürk E, Steinwachs M, Skjåki-Bræk G, Zenobi-Wong M. Biomimetic sulphated alginate hydrogels suppress IL-1B-induced inflammatory responses in human chondrocytes. *Eur Cells Mater.* 2017;33:76–89. <https://doi.org/10.22203/eCM.v033a06>.
- [144] Denoix JM, Thibaud D, Riccio B. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. *Equine Vet J.* 2003;35:407–13. <https://doi.org/10.2746/042516403776014226>.
- [145] Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Gührlke S, et al. Palliation and survival after repeated ¹⁸⁷Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. *J Nuc Med.* 2011;52:1721–6. <https://doi.org/10.2967/jnumed.111.093674>.

- [146] Beek EV, löwik C, Pluijm GD, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. *J Bone Min Res.* 1999;14:722–9. <https://doi.org/10.1359/jbmr.1999.14.5.722>.
- [147] Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. *Pro Natl Acad Sci U S A.* 2006;103:7829–34. <https://doi.org/10.1073/pnas.0601643103>.
- [148] Baas T. Rebuilding a better bone. *Sci-Bus eXchange.* 2012;5:194. <https://doi.org/10.1038/scibx.2012.194>.
- [149] Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S. Neridronic acid for the treatment of bone metabolic diseases. *Expert Opin Drug Metab Toxicol.* 2009;5:1305–11. <https://doi.org/10.1517/17425250903029190>.
- [150] Otto S. Medication-related Osteonecrosis of the Jaws. Bisphosphonates, Denosumab, and New Agents. Berlin Heidelberg: Springer-Verlag; 2015; 207–15 ISBN https://doi.org/10.1007/978-3-662-43733-9_20.
- [151] Sugisaki M. Clinical coping with bisphosphonate-induced osteonecrosis of the jaws. *Tokyo Jikeikai Med J.* 2011;126:59–70.
- [152] PMDA. Releases updates for levetiracetam. *Bisphosphonates Scholar J.* 2016;4.
- [153] Min B, Song K, Bae K, Cho C, Son E, Lee K. Nonsurgical treatment strategies after osteoporotic hip fractures. *Hip Pelvis.* 2015;27:9–16. <https://doi.org/10.5371/hp.2015.27.1.9>.
- [154] Chaplin S, Dennison E. Zoledronic acid: a once-yearly injection for osteoporosis. *Prescriber.* 2008;19:40–4. <https://doi.org/10.1002/psb.254>.
- [155] Kimoto A, Tanaka M, Nozaki K, Mori M, Fukushima S, Mori H, et al. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment. *Bone.* 2013;55:189–97. <https://doi.org/10.1016/j.bone.2013.02.013>.
- [156] Pratt RD, Swinkels DW, Ikizler TA, Gupta A. Pharmacokinetics of ferric pyrophosphate citrate, a novel iron salt, administered intravenously to healthy volunteers. *J Clin Pharmacol.* 2016;57:312–20. <https://doi.org/10.1002/jcph.819>.
- [157] Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guess CD, et al. Ferric pyrophosphate citrate (TrifericTM) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. *Nephrol Dial Transplant.* 2015;30:2019–26. <https://doi.org/10.1093/ndt/gfv277>.
- [158] Jordan F. Semiempirical calculations on the electronic structure and preferred conformation of thiamine (vitamin b1) and thiamine pyrophosphate (cocarboxylase). *J Am Chem Soc.* 1974;96:3623–30. <https://doi.org/10.1021/ja00818a041>.
- [159] Ames TD, Sharik ME, Rather GM, Hochart G, Bonnel D, Linehan S, et al. Translational research of PT-112, a clinical agent in advanced phase I development: evident bone tropism, synergy in vitro with bortezomib and lenalidomide, and potent efficacy in the Vk*MYC mouse model of multiple myeloma. *Blood.* 2017;130:1797. https://doi.org/10.1182/blood.V130.Suppl_1.1797.1797.
- [160] Secades JJ. Citicoline: Pharmacological and Clinical Review, 2010 Update. *Rev Neurol.* 2011; 52: S1-S62. doi:10.33588/rn.52S02.2010787.
- [161] Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, et al. Cytidine 51-diphosphocholine (citicoline) in glaucoma: rationale of its use, current evidence and future perspectives. *Int J Mol Sci.* 2015;16:28401–17. <https://doi.org/10.3390/ijms161226099>.
- [162] Baile M, Giancaspero T, Brizio C, Panebianco C, Indiveri C, Galliccio M, et al. Biosynthesis of flavin cofactors in man: implications in health and disease. *Curr Pharm Des.* 2013;19:2649–75. <https://doi.org/10.2174/1381612811319140014>.
- [163] Keating GM. Cangrelor: a review in percutaneous coronary intervention. *Drugs.* 2015; 75:1425–34. <https://doi.org/10.1007/s40265-015-0445-3>.
- [164] Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. *Am Heart J.* 2008;156:10–5. <https://doi.org/10.1016/j.ahj.2008.06.004>.
- [165] Pendergast W, Yerxa BR, Douglass JG, Shaver SR, Dougherty RW, Redick CC, et al. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. *Bioorg Med Chem Lett.* 2000;11:157–60. [https://doi.org/10.1016/S0960-894x\(00\)00612-0](https://doi.org/10.1016/S0960-894x(00)00612-0).
- [166] Fingert HJ, Pu AT, Chen Z, Googe PB, Alley MC, Pardee AB. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. *Cancer Res.* 1988;48:4375–81.
- [167] Kaldor JM, Day NE, Kittelmann B, Pettersson F, Langmark F, Pedersen D, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. *Int J Cancer.* 1995;63:1–6. <https://doi.org/10.1002/ijc.2910630102>.
- [168] Gao J, Yoon K, Frisbie RK, Coles GC, Clark JM. Esterase-mediated malathion resistance in the human head louse, *Pediculus capitis* (Anoplura: Pediculidae). *Pestic Biochem Physiol.* 2006;85:28–37. <https://doi.org/10.1016/j.pestbp.2005.09.003>.
- [169] Kean WF, Hart L, Buchanan WW. Disease-modifying drugs series Editor: T. Pullar-Auranofin. *Brit J Rheumatol.* 1997;36:560–72.
- [170] Marzo T, Messori L. A Role for metal-based drugs in fighting COVID-19 infection? The case of auranofin. *ACS Med Chem Lett.* 2020;11:1067–8. <https://doi.org/10.1021/acsmchemlett.0c00190>.